Replimune (REPL) Capital Expenditures (2017 - 2026)

Replimune has reported Capital Expenditures for 10 years, with the latest figure at $80000.0 in Q1 2026.

• Quarterly Capital Expenditures rose 157.97% year-over-year to $80000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80000.0 (down 53.22% YoY) and the FY2026 annual result came in at $80000.0, down 53.22% from the prior year.
• Capital Expenditures rose to $80000.0 in Q1 2026 per REPL's latest filing, from -$177000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $5.7 million in Q1 2024 and troughed at -$3.4 million in Q4 2024.
• A 5-year average of $308647.1 and a median of $80000.0 in 2026 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 770.1% in 2024, down 2395.65% in 2024.
• Over 5 years, Capital Expenditures stood at $555000.0 in 2022, then plunged by 124.86% to -$138000.0 in 2023, then plunged by 2395.65% to -$3.4 million in 2024, then jumped by 94.86% to -$177000.0 in 2025, then surged by 145.2% to $80000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $80000.0, -$177000.0, and -$2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.